Rilogrotug (AV-380)
Cancer Cachexia
Phase 1/2Active
Key Facts
About AVEO Oncology
AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.
View full company profileTherapeutic Areas
Other Cancer Cachexia Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM120 | NGM Biopharmaceuticals | Phase 2 |
| Mifomelatide (TCMCB07) | Endevica Bio | Phase 2 |
| Espindolol (MT-102) | Numedicus | Phase 2/Spin-out |
| S-pindolol benzoate (ACM-001.1) | Actimed Therapeutics | Phase 2 |